

1 **The Bacterial Profile and Antibiotic Susceptibility Pattern in Respiratory Tract Samples from**
2 **ART-Experienced HIV-Positive Adults in Uganda.**

3

4 **Authors**

5 Lubega Gloria^{1*}, Abaasa Andrew^{1,4}, Willyfred Ochola¹, Bernard Kikaire^{2,3}, Joseph Lutaakome¹,
6 Eugene Rugazira^{1,4}, Yunia Mayanja^{1,4}

7 1. Medical Research Council /Uganda Virus Research Institute and London School of
8 Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda

9 2. Uganda Virus Research Institute, Entebbe, Uganda

10 3. Department of paediatrics, College of Health Sciences, Makerere University, Kampala,
11 Uganda

12 4. London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT

13

14 ***Corresponding author:**

15 Email: Gloria.Lubega@mrcuganda.org (LG)

16

17

18

19

20

21

22

23 Abstract

24 **Introduction:** Microbial infections are a major cause of morbidity and mortality among people
25 living with HIV (PLWH). Respiratory tract infections (RTIs) are responsible for approximately 70%
26 of illnesses among PLWH. Drug resistant bacteria are highly prevalent among PLWH and this is a
27 public health concern.

28 **Methods:** This is a retrospective analysis of data collected during the COSTOP trial between 2011
29 and 2013. Sputum collected on spot from participants presenting with a productive cough was
30 examined using Gram, Ziehl-Neelsen stains and cultured on suitable bacteriological media.
31 Antimicrobial sensitivity testing was done on isolated pathogens, by disc diffusion technique.

32 **Results:** We included 687 participants with mean age 41.3 (SD 8.2) years of whom 76.4% were
33 female. Two hundred one sputum samples grew bacteria; *Moraxella species* (27.4%),
34 *Streptococcus pneumoniae*(25.4%), *Haemophilus influenza*(22.4%), *Mycobacterium*
35 *species*(4.5%), *Pseudomonas species*(4.0%), *Staphylococcus aureus*(4.0%), *Escherichia coli* (1.0%),
36 *Klebsiella species* (1.0%), other bacteria (10.4%). A higher monthly income greater than or equal
37 to 30\$ (aOR= 0.63, 95%CI: 0.40-0.99) and longer duration since HIV diagnosis (aOR= 1.06, 95%CI:
38 1.0-1.11) were found to be independently associated with a positive bacterial culture. *Moraxella*
39 *sp*, *H. influenza* and *Pseudomonas* had zero sensitivity towards cotrimoxazole. Sensitivity to
40 erythromycin was low among *Moraxella sp* (28.6%), *H. influenza* (31.6%) and *S. aureus*(42.9%)
41 and other bacteria (42.9%). Most isolates were sensitive to Amoxicillin + Clavulanic acid and
42 ceftriaxone.

43 **Conclusion:** There is a very low sensitivity of isolated bacteria to commonly prescribed antibiotics
44 that are more available through the national supply chain, which is of public health concern.
45 Urgent steps to tackle the high antimicrobial resistance among PLWH is required.

46

47 **Keywords:** PLWH, Bacteria, Antimicrobial Susceptibility, Antibiotic, Respiratory tract Infection

48

49 **Abbreviations**

50 API – Analytical profile index

51 AMR – Antimicrobial Resistance

52 ART - Antiretroviral therapy

53 CD4 - Cluster of Differentiation 4

54 COSTOP - Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults in
55 Uganda: a randomised controlled trial

56 EUCAST - European Committee on Antimicrobial Susceptibility Testing

57 HIV – Human Immune Deficiency Virus

58 PLWH – People living with HIV

59 RTIs – Respiratory tract infections

60 SSA - Sub-Saharan Africa

61

62

64 **Introduction**

65 For over three decades, Human Immunodeficiency Virus (HIV) infection remains a disease of
66 public health importance with approximately 37.6 million people living with HIV (PLWH) globally
67 in 2020 (1). Sub-Saharan Africa (SSA) suffers the highest burden of HIV with nearly 70% of global
68 HIV infections (2). Since the introduction of antiretroviral therapy (ART), PLWH have an improved
69 quality of life however, microbial infections are still a major cause of morbidity and mortality
70 among this population (3), with approximately 70% of illnesses being respiratory tract infections
71 (RTIs) (4, 5). Ojha et al. reported a high prevalence (47%) of respiratory tract infections caused by
72 bacterial pathogens among PLWH(5) and, factors associated with these infections include low
73 CD4 counts (<200 cells/ μ l) and detectable viral loads (5, 6).

74 HIV infection causes a progressive depletion of CD4 T cells as well as an impairment of cellular
75 and humoral immunity through a dysfunction of the T and B cells respectively (7). A dysfunction
76 of T cells leads to abnormal cellular responses while a dysfunction of B cells leads to a lack of
77 antibody responses to infections. The resultant immune dysfunction, deregulation and depletion
78 of CD4 lymphocytes causes an increased susceptibility to infections and the subsequent risk of
79 other complications like resistant pathogens (8, 9). HIV infection causes an alteration in lung host
80 defences for example, it affects mucociliary function which may contribute to an increase RTIs
81 among PLWH (9). PLWH are at increased risk of hospital acquired infections due to their frequent
82 contact with health care system through frequent clinic visits and admissions (10). The frequent
83 infections and admissions among PLWH, pill burden leading to unfinished doses and
84 inappropriate use of drugs through self-medication are some of the factors that have led to the
85 development of antimicrobial resistance among this population (11).

86 Antimicrobial resistance is an emerging global problem of public health importance (4). Previous
87 studies have reported a much higher prevalence of drug resistant bacteria among PLWH (79%)
88 compared to their HIV negative counterparts (30%) (10, 12). Prophylactic cotrimoxazole given to
89 PLWH over prolonged periods of time to prevent opportunistic infections has been reported to
90 give rise to antibiotic resistance (13). Resistant microbes are more difficult to manage since they
91 require alternative medications and or higher doses of drugs, both of which are more expensive,
92 not readily available in SSA and or toxic to the patient (13). Additionally, laboratory capacity for
93 identifying AMR is still limited in many parts of SSA; data are therefore still limited on
94 antimicrobial susceptibility patterns among PLWH in SSA (10). (10). It is important to understand
95 the common disease-causing pathogens among PLWH and current antibiotic susceptibility
96 patterns for better management. We studied the susceptibility pattern of microorganisms
97 isolated from respiratory samples taken from PLWH in central Uganda.

98 **Methods**

99 **Study design, setting:** We conducted a retrospective analysis of data collected during the
100 COSTOP trial (*Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults in*
101 *Uganda: a randomised controlled trial, ISRCTN44723643*) conducted between January 2011 and
102 March 2013 in two HIV care clinics in Masaka and Entebbe in central Uganda. (14, 15).
103 The COSTOP trial enrolled HIV positive adults (≥ 18 years) who had been on ART and
104 cotrimoxazole prophylaxis for at least six months, clinically asymptomatic and had CD4 cell
105 counts of >250 cells/mm³ prior to enrolment. Individuals who had an acute illness, grade three

106 or four anaemia, neutropenia or thrombocytopenia, known hypersensitivity to cotrimoxazole,
107 and pregnant women were excluded.

108 **Participants and Eligibility**

109 The current analysis included COSTOP trial participants who presented to the clinic with a
110 productive cough and provided sputum at any time during the trial. Participants were asked to
111 collect sputum in a dry, leak proof, sterile container after rinsing their mouth with water. Samples
112 were immediately transported to the laboratory for microscopy, culture, and sensitivity.

113 **Laboratory:** Samples were examined microscopically using Gram, Ziehl-Neelsen stains and
114 cultured on suitable bacteriological media (Blood, Chocolate, MacConkey agar and Subouroid
115 agar). Samples were incubated at 37⁰c for 24hrs, the pathogens that grew from incubated
116 samples were identified microscopically and biochemically using analytical profile index (API) and
117 by sensitivity testing. Antimicrobial sensitivity testing was done on isolated pathogens, by disc
118 diffusion technique(16). The diameter of the zone of inhibition was measured and compared to
119 that of European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards(17) to
120 determine resistance or sensitivity of a pathogen to the antimicrobial.

121 **Study variables**

122 The dependent variable was bacterial culture positivity of sputum collected during the study. The
123 independent variables were gender, age (years) categorized under age groups <35years, 35-55
124 years and >55 years, recent and initial CD4 counts categorized into <200, 200-300 and >300
125 cells/ul, study arm in the COSTOP trial (cotrimoxazole arm, placebo arm), highest education level
126 attained categorized into none, primary and secondary school, marital status categorized into
127 married, divorced and single, monthly income (\$) categorized into those earning <30 and >=30,

128 ART regimen categorized into First line and second line, duration on ART (years) and period since
129 HIV diagnosis (years).

130 **Statistical analysis:** The data collected were managed in MS Access, 2003 (Microsoft
131 Corporation, Redmond, WA) and data analyses were performed using Stata 14 (Stata Corp,
132 College Station, Texas 77845 USA) [11]. Continuous variables were presented as means with
133 standard deviation (SD) and categorical variables as frequencies and percentages. The proportion
134 of bacterial culture positivity overall, and by different participant characteristics were
135 determined as number culture positive divided by the total sample, expressed as a percentage.
136 A bar graph was used to display the frequency of bacterial isolates, and frequency and
137 percentages used to summarise antibacterial susceptibility of bacteria isolated in sputum. To
138 determine factors associated with bacterial culture positivity, we fitted both univariable and
139 multivariable logistic regression models. At univariable analysis, all factors in logit models with
140 likelihood ratio test p-value <0.2, were selected for multivariable logit model. Factors were
141 retained in the multivariable logit model if their inclusion did not make the model fit significantly
142 worse at p<0.05 on likelihood ratio test. We present the results as adjusted odds ratios (AOR)
143 with corresponding 95% confidence intervals (CI)

144 **Results**

145 **Participants' characteristics**

146 We included 687 participants in the analysis with mean age was 41.3 years (SD ±8.23) and 76.4%
147 were female. Overall, 51.1% of participants received cotrimoxazole, 70.2% earned less than \$30
148 monthly and 60.3% had primary level education. We observed that the mean period since HIV

149 diagnosis was 5.49 years (SD \pm 4.50) and the mean period on ART was 3.79 years (SD \pm 1.86) with
 150 97.9% of participants on a first line ART regimen. Regarding CD4 counts, 89.7% had a recent CD4
 151 of >300cell/ μ l however, 68.4% had a nadir CD4 count of <200cell/ μ l (Table 1).

152**Table 1:** Factors associated with bacterial growth in sputum cultures among ART-experienced HIV-
 153positive individuals in Uganda (N=687)

Characteristic	N =687 n(%)	Culture positive (%)	OR (95% CI)	P-value	AOR (95% CI)	P-value
Sex						
Female	525 (76.4)	113 (21.5)	1		1	
Male	162 (23.6)	43 (26.5)	1.32 (0.88-1.98)	0.183	1.37 (0.89-2.11)	0.156
Age (years)						
<35	161 (23.4)	40 (24.8)	1			
35-55	482 (70.2)	110 (22.8)	0.89 (0.59-1.36)	0.599	0.91 (0.59-1.41)	0.666
>55	44 (6.4)	6 (13.6)	0.48 (0.19-1.21)	0.120	0.43 (0.17-1.13)	0.086
Receiving cotrimoxazole						
cotrimoxazole	351 (51.1)	71 (20.2)	1			
placebo	336 (48.9)	85 (25.3)	1.34 (0.93-1.91)	0.113	1.37 (0.94-1.98)	0.098
Education level						
None	101 (14.7)	26 (25.7)	1			
Primary	414 (60.3)	91 (22.0)	0.81 (0.49-1.34)	0.419		
Secondary	172 (25.0)	39 (22.7)	0.85 (0.48-1.50)	0.566		
Marital status						
Married	284 (41.3)	62 (21.8)	1			
Divorced	377 (54.9)	88 (23.3)	1.09 (0.75-1.58)	0.646		
Single	26 (3.8)	06 (23.1)	1.07 (0.41-2.79)	0.883		
Monthly income (\$)						
<30	448 (70.2)	109 (24.3)	1			
\geq 30	190 (29.8)	38 (20.0)	0.78 (0.51-1.18)	0.236	0.63 (0.40-0.99)	0.049
Recent CD4*						
<200	11 (1.6)	1 (9.1)	1			
200-300	58 (8.4)	18 (31.0)	4.50 (0.53-37.85)	0.166	5.09 (0.58-44.60)	0.141
>300	616 (89.7)	137 (22.2)	2.86 (0.36-22.54)	0.318	2.86 (0.35-23.44)	0.326
Nadir CD4*						
<200	470 (68.4)	105 (22.3)	1			
200-300	123 (17.9)	30 (24.4)	1.12 (0.70-1.79)	0.629		
>300	18 (2.6)	4 (22.2)	0.99 (0.32-3.08)	0.991		
ART regimen*						
First line	662 (97.9)	151 (22.8)	1			
Second line	14 (2.1)	1 (7.1)	0.26 (0.03-201)	0.196	0.24 (0.03-1.94)	0.180

Duration on ART, (mean (SD)) yrs	3.79 (1.86)	3.75 (1.84)	0.98 (0.89-1.08)	0.726		
Years since HIV diagnosis, (mean (SD)) yrs	5.49 (4.50)	6.20 (6.83)	1.04 (1.00-1.09)	0.053	1.06 (1.01-1.11)	0.025

154 ART = antiretroviral therapy; HIV = Human Immunodeficiency Virus

155

156 Bacterial culture positivity and prevalence of isolated microorganisms

157 A total of 201 (29.3%) samples had bacterial growth, with 9 samples growing more than one
 158 bacterial organism. Isolated bacteria included *Moraxella species* (55, 27.4%), *Streptococcus*
 159 *pneumoniae* (51, 25.4%), *Haemophilus influenza* (45, 22.4%), *Mycobacterium species* (11, 4.5%),
 160 *Pseudomonas species* (8, 4.0%), *Staphylococcus aureus* (8, 4.0%), *Escherichia coli* (2, 1.0%),
 161 *Klebsiella species* (2, 1.0%) and other bacteria (19, 10.4%) (Figure 1).

162 Factors associated with bacterial culture positivity

163 The factors found to be independently associated with having a bacterial culture positive sample
 164 where; monthly income \geq \$30 (aOR= 0.63, 95%CI 0.40-0.99) compared to those earning below
 165 \$30 and longer duration of years since HIV diagnosis [aOR= 1.06, 95% CI 1.01-1.11]. Participants
 166 who received placebo were more likely to have a positive sputum culture than those who
 167 received cotrimoxazole however this was not found to have statistical significance (aOR= 1.37,
 168 95% CI 0.94-1.98) (Table 1).

169 Antibiotic sensitivity of isolated microorganisms

170 The sensitivity of bacterial isolates is shown in Table 2. Most isolates were highly sensitive to
 171 Amoxicillin + Clavulanic acid and ceftriaxone with *Moraxella sp. and, Streptococcus pneumoniae*
 172 having 100% sensitivity to both. *Pseudomonas* had 100% sensitivity to gentamycin while H.
 173 *influenza* showed 100% sensitivity to ceftriaxone and 88.6% sensitivity to Amoxicillin + Clavulanic
 174 acid. Other bacteria showed the highest sensitivity to ceftriaxone and gentamycin (85.7%).

175 All isolates had very low sensitivity to cotrimoxazole (<16.7%). *Moraxella sp*, *H. influenza* and *Pseudomonas* showed zero sensitivity to
 176 cotrimoxazole. *Moraxella sp* (28.8%), *H. influenza* (31.6%), *S. aureus* (42.9%) and other bacteria (42.9%) also had low sensitivity
 177 towards erythromycin. *H. influenza* (50.0%) and other bacteria (69.2%) had relatively low sensitivity towards ciprofloxacin.

178 **Table 2:** Antibacterial susceptibility rates of bacterial isolated from sputum of PLWH.
 179

	<i>Moraxella species</i>			<i>Streptococcus pneumoniae</i>			<i>Haemophilus influenza</i>			<i>Pseudomonas species</i>			<i>Staphylococcus aureus</i>			<i>Others</i>		
	N=55			N=51			N=45			N=8			N=8			N=34		
	T	S	S%	T	S	S%	T	S	S%	T	S	S%	T	S	S%	T	S	S%
Cotrimoxazole	43	0	0.0	39	1	2.6	37	0	0.0	3	0	0.0	6	1	16.7	21	2	9.5
Erythromycin	42	12	28.6	38	30	78.9	38	12	31.6	0	0	n/a	7	3	42.9	7	3	42.9
Amoxyl+clavulanic acid	42	42	100.0	4	4	100.0	35	31	88.6	0	0	n/a	6	6	100.0	7	6	85.7
ciprofloxacin	0	n/a	n/a	0	n/a	n/a	2	1	50.0	5	4	80.0	0	n/a	n/a	13	9	69.2
Ceftriaxone	2	2	100.0	35	35	100.0	1	1	100.0	2	1	50.0	0	n/a	n/a	13	10	76.9
Gentamycin	0	n/a	n/a	0	n/a	n/a	0	0	n/a	5	5	100.0	0	n/a	n/a	14	12	85.7

180 NOTE: Amoxyl + clavulanic acid = Amoxicillin + Clavulanic acid, T = number tested, S = sensitivity

181

182 Discussion

183 We cultured sputum from ART experienced PLWH with a productive cough and approximately
184 30% of the sputum samples had bacterial growth. This is similar to what was reported by
185 Akingbade OA et al who found a prevalence of 24.2% positive cultures from sputum collected
186 from participants with lower RTIs (18), but lower than approximately 44% prevalence reported
187 by Adhanom et al (19). Adhanom et al included both ART experienced and ART naïve participants
188 that were suspected of pneumonia, which more a severe disease than the presentation of cough
189 that was considered in our study. Our participants were all ART experienced, indicating they
190 might have had a better immunity than those included in Adhanom et al study. Additionally,
191 Adhanom et al's study was conducted in three years after the COSTOP study, during which
192 period there might have been an increase in antimicrobial resistance, leading to reduced
193 response by the bacteria to antibiotics hence increased bacterial growth on culture.

194 We found a high prevalence of *Moraxella species* (28%) in our sputum samples. *Moraxella species*
195 is usually normal flora of the respiratory tract, however, previous studies have reported
196 *Moraxella* as a pathogen of the lower respiratory tract in immunosuppressed patients (20).
197 Abdullah et al reported a relatively high prevalence of *Moraxella* in patients with lower RTIs
198 among the elderly and immunosuppressed (20). Our finding of high proportion of participants
199 with *Moraxella species* may indicate a less than complete immune recovery in these patients.

200 The *Moraxella species* isolated in our study was sensitive to amoxicillin+ clavulanic acid and
201 ceftriaxone and had very low sensitivity to erythromycin and cotrimoxazole, which is similar to
202 what Abdullah et al reported (20). The very low sensitivity of all the bacterial isolates to

203 cotrimoxazole is not surprising since our study participants were either on active cotrimoxazole
204 prophylaxis, or had previously used cotrimoxazole prophylaxis.

205 HIV infection leads to a low CD4 count and a defective immune system which renders people
206 infected with the HIV virus susceptible to microbial infections leading to a greater use of
207 antibiotics among people living with HIV. The increased use of antibiotics may explain the
208 observed low sensitivity of isolated bacteria to cotrimoxazole (21), and erythromycin (20) among
209 PLWH in this study and other studies.

210 Participants that received placebo were more likely to have a positive sputum culture compared
211 to those receiving cotrimoxazole, however this was not statistically significant. This implies that
212 use of Cotrimoxazole did not provide protection against respiratory infections in this study
213 population. This could be due to the fact that the study participants were ART experienced, had
214 improved and stabilised immunity, and thus were no longer susceptible to infections associated
215 with compromised immunity. Although the study was not powered to answer the question on
216 the effect of cotrimoxazole on respiratory bacterial infections, this finding supports the 2020
217 Uganda HIV prevention and treatment guidelines that recommends use of prophylactic
218 cotrimoxazole only in adults with advanced HIV disease, those newly diagnosed with HIV,
219 children below 18years, pregnant and breastfeeding women(22). An association of long term use
220 of cotrimoxazole among PLWH with an increase in resistance to cotrimoxazole has been reported
221 in previous studies (23, 24) therefore, reduced use of cotrimoxazole in this population may
222 reduce resistance of microbes to it.

223 The participants in the study were generally low earners as majority of them were earning less
224 than \$30 a month. Participants who earned more than \$30 were less likely to have positive

225 bacterial cultures compared to those who earned less than \$30. This is similar to evidence that
226 suggests that those with lower socio-economic status are more vulnerable, have higher burden
227 of disease and thus more prone to frequent respiratory infections (25).

228 Participants who had a longer duration since HIV diagnosis were more likely to have a positive
229 bacterial culture. This finding requires further investigation since there is no clear biological
230 explanation between duration of HIV infection and risk of bacterial infections.

231 **Strengths and Limitations**

232 This study among ART experienced participants has applicable results as majority of PLWH are
233 on ART following the test and treat policy. Previous studies have mainly reported antimicrobial
234 sensitivity among ART naïve patients. The study was however, a secondary data analysis and this
235 limited the number of antimicrobial drugs that could have been tested for bacterial sensitivity.
236 We could also not explore other factors for example viral load, that could be associated with a
237 positive sputum culture.

238 **Conclusion**

239 High prevalence of bacterial isolates with most being susceptible to Amoxicillin + Clavulanic acid
240 and ceftriaxone. However, majority of organisms showed very low sensitivity to cotrimoxazole
241 and erythromycin that are cheaper and readily available. As antibiotic choices are becoming
242 limited due to low sensitivity of microbes to these drugs, there is an urgent need to invest in the
243 prevention and control of increasing antibiotic resistance.

244 **Acknowledgements**

245 We would like to acknowledge the contributions of the COSTOP trial team and the contribution
246 of the study participants

247 **Competing interests**

248 The authors declare no competing interests.

249 **Ethical approval statement**

250 All participants enrolled into the main COSTOP trial gave written informed consent prior to any
251 study procedures. The COSTOP study received approval from Uganda Virus Research Institute
252 Ethics committee, National Drug Authority and Uganda National Council for Science and
253 Technology.

254 **Author Contributions:**

255 LG conceived and designed the study, participated in data collection, analysis and interpretation,
256 AA contributed to data analysis. All authors read, revised the original manuscript and approved
257 the final version of manuscript.

258

259 **References**

- 260 1. UNAIDS. Global HIV & AIDS statistics - Fact sheet 2021 [Available from:
261 [https://www.unaids.org/en/resources/fact-](https://www.unaids.org/en/resources/fact-sheet#:~:text=GLOBAL%20HIV%20STATISTICS,AIDS%2Drelated%20illnesses%20in%202020)
262 [sheet#:~:text=GLOBAL%20HIV%20STATISTICS,AIDS%2Drelated%20illnesses%20in%202020](https://www.unaids.org/en/resources/fact-sheet#:~:text=GLOBAL%20HIV%20STATISTICS,AIDS%2Drelated%20illnesses%20in%202020).
263 2. Barankanira E, Molinari N, Niyongabo T, Laurent C. Spatial analysis of HIV infection and
264 associated individual characteristics in Burundi: indications for effective prevention. BMC Public Health.
265 2016;16(1):118.
266 3. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission
267 among people living with HIV worldwide: a systematic review and meta-analysis. The lancet HIV.
268 2015;2(10):e438-44.
269 4. Gauchan P, Lekhak B, Sherchand JB. The prevalence of lower respiratory tract infection in adults
270 visiting Tribhuvan University Teaching Hospital. Journal of Institute of Medicine Nepal. 2007;28(2):10-4.
271 5. Ojha CR, Rijal N, Khagendra KC, Palpasa K, Kansakar P, Gupta BP, et al. Lower respiratory tract
272 infections among HIV positive and control group in Nepal. VirusDisease. 2015;26(1):77-81.

- 273 6. Lamas CC, Coelho LE, Grinsztejn BJ, Veloso VG. Community-acquired lower respiratory tract
274 infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study.
275 *Infection*. 2017;45(6):801-9.
- 276 7. Cairns G. HIV damages B-cells as well as T-cells: new treatment targets identified NAM-
277 aidsmap2011 [Available from: [https://www.aidsmap.com/news/jun-2011/hiv-damages-b-cells-well-t-](https://www.aidsmap.com/news/jun-2011/hiv-damages-b-cells-well-t-cells-new-treatment-targets-identified)
278 [cells-new-treatment-targets-identified](https://www.aidsmap.com/news/jun-2011/hiv-damages-b-cells-well-t-cells-new-treatment-targets-identified)].
- 279 8. Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological
280 failure. *Immunol Rev*. 2013;254(1):54-64.
- 281 9. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection
282 and risk for incident pulmonary diseases in the combination antiretroviral therapy era. *American journal*
283 *of respiratory and critical care medicine*. 2011;183(3):388-95.
- 284 10. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association
285 between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. *Clinical*
286 *microbiology and infection : the official publication of the European Society of Clinical Microbiology and*
287 *Infectious Diseases*. 2021;27(6):846-53.
- 288 11. Rameshkumar MR, NarasingamArunagirinathan, editors. *Drug-Resistant Bacterial Infections in*
289 *HIV Patients*2018.
- 290 12. Marbou WJT, Kuete V. Bacterial resistance and immunological profiles in HIV-infected and non-
291 infected patients at Mbouda AD LUCEM Hospital in Cameroon. *Journal of Infection and Public Health*.
292 2017;10(3):269-76.
- 293 13. Arunagirinathan MRRaN. *Drug-Resistant Bacterial Infections in HIV Patients, Advances in HIV*
294 *and AIDS Control*. IntechOpen. 2018.
- 295 14. Anywaine Z, Abaasa A, Levin J, Kasirye R, Kamali A, Grosskurth H, et al. Safety of discontinuing
296 cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP
297 trial): Design. *Contemporary clinical trials*. 2015;43:100-4.
- 298 15. Anywaine Z, Levin J, Kasirye R, Lutaakome JK, Abaasa A, Nunn A, et al. Discontinuing
299 cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in
300 Uganda (COSTOP): A randomised placebo controlled trial. *PloS one*. 2018;13(12):e0206907.
- 301 16. Novick Jr WJ. Development of in vitro susceptibility testing criteria and quality control
302 parameters. Elsevier; 1989. p. 60-2.
- 303 17. Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in
304 antimicrobial susceptibility testing. *Clinical Microbiology and Infection*. 2013;19(2):141-60.
- 305 18. A A, Ogiogwa J, Okerentugba P, Innocent-Adiele C, Onoh C, Nwanze J, et al. Prevalence of
306 Antibiotic Susceptibility Pattern of bacterial Agents Involve In lower Respiratory Tract Infection in
307 Abeokuta ,Ogun State ,Nigeria. *Report and Opinion*. 2012.
- 308 19. Adhanom G, Gebreegziabiher D, Weldu Y, Gebreyesus Wasihun A, Araya T, Legese H, et al.
309 Species, Risk Factors, and Antimicrobial Susceptibility Profiles of Bacterial Isolates from HIV-Infected
310 Patients Suspected to Have Pneumonia in Mekelle Zone, Tigray, Northern Ethiopia. *BioMed Research*
311 *International*. 2019;2019:8768439.
- 312 20. Abdullah FE, Ahuja KR, Kumar H. Prevalence and emerging resistance of *Moraxella catarrhalis* in
313 lower respiratory tract infections in Karachi. *JPMA The Journal of the Pakistan Medical Association*.
314 2013;63(11):1342-4.
- 315 21. Oguiche JI-o, Bolaji RO, Onaolapo JA, Abah SE, Kwaghe VG, Akor SE, et al. BACTERIAL INFECTION
316 AND ANTIBIOTIC RESISTANCE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS PRESENTING
317 LOWER RESPIRATORY TRACT INFECTION IN NIGERIA. *medRxiv*. 2021:2021.09.05.21263138.
- 318 22. Health Mo. CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND
319 AIDS IN UGANDA 2020 [Available from:

320 https://differentiatedservicedelivery.org/Portals/0/adam/Content/HvpzRP5yUUSdpCe2m0KMdQ/File/Uganda_Consolidated%20HIV%20and%20AIDS%20Guidelines%202020%20June%2030th.pdf.

322 23. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of
323 trimethoprim-sulfamethoxazole resistance in the AIDS era. *The Journal of infectious diseases*.
324 1999;180(6):1809-18.

325 24. Zachariah R, Harries AD, Spielmann MP, Arendt V, Nchingula D, Mwenda R, et al. Changes in
326 *Escherichia coli* resistance to co-trimoxazole in tuberculosis patients and in relation to co-trimoxazole
327 prophylaxis in Thyolo, Malawi. *Malawi medical journal : the journal of Medical Association of Malawi*.
328 2002;14(2):10-2.

329 25. Kiwanuka SN, Ekirapa EK, Peterson S, Okui O, Rahman MH, Peters D, et al. Access to and
330 utilisation of health services for the poor in Uganda: a systematic review of available evidence.
331 *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2008;102(11):1067-74.

332

Frequency of bacterial isolates




Fig. 1 Frequency of bacterial isolates.
Figure